BAY-3563254

N/A

Report date: 2026/04/03 20:03:44

NME

Base Information

Drug NameBAY-3563254

Drug Alias NamePSMA SMOL TACAc 225 conjugated small moleculeActinium-labeled PSMA-targeted alpha therapy225Ac-PSMA-TrilliumBAY-3563254 +[6]

ClassificationRadiation-emitting products > Radioactive therapeutic agentSmall molecules > Heterocyclic drugsRadiation-emitting products > Nuclides > Actinium > 225Ac +[4]

Mechanisms of ActionIonising radiation emittersProstate-Specific Membrane Antigen modulators

TargetsProstate-Specific Membrane Antigen

Therapy Area/IndicationsProstatismProstatic Neoplasms, Castration-ResistantProstatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBelgiumCanadaUnited States +[11]

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesPSMA Therapeutics Inc Noria Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesBayer AG

Inactive CompaniesN/A

Active IndicationsProstatismProstatic Neoplasms, Castration-ResistantProstatic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A